



Hepatic Insulin Resistance and Whole-Body Outcomes

Guest Editors:

Dr. Terry D Hinds, Jr.

Prof. Dr. Sonia Michael Najjar

Dr. Brett Spear

Dr. David E. Stec

Deadline for manuscript
submissions:

closed (25 October 2021)

Message from the Guest Editors

Dear Colleagues,

Non-alcoholic fatty liver disease (NAFLD) has risen worldwide in parallel to the rise in obesity and metabolic syndrome. Metabolic syndrome is marked by insulin resistance and is manifested in part by altered insulin and lipid metabolism. The liver is a major site of insulin clearance that, together with insulin secretion, determines the systemic insulin level that regulates insulin's action in peripheral tissues. Dysregulation of this process leads to hepatic and systemic insulin resistance, type 2 diabetes, and its cardiovascular complications.

This Special Issue focuses on the central role that the liver plays in regulating insulin and fat metabolism, and how this may interact with adipocytes to regulate whole-body insulin sensitivity and cardiovascular functions.

Dr. Terry D. Hinds

Prof. Dr. Sonia Michael Najjar

Dr. Brett Spear

Dr. David E. Stec

Guest Editors

